Patents Assigned to Sol-Gel Technologies Ltd.
-
Patent number: 11877997Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.Type: GrantFiled: January 25, 2021Date of Patent: January 23, 2024Assignee: Sol-Gel Technologies Ltd.Inventors: Ofer Toledano, Ofra Levy-Hacham, Ori Nov, Vered Ram
-
Patent number: 11865208Abstract: Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w/w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.Type: GrantFiled: September 17, 2020Date of Patent: January 9, 2024Assignee: Sol-Gel Technologies Ltd.Inventors: Marina Shevachman, Amira Ze' Evi, Eilon Asculai, Batella Benyaminovich, Nir Avram, Chaim Aschkenasy
-
Patent number: 11865100Abstract: A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.Type: GrantFiled: January 21, 2021Date of Patent: January 9, 2024Assignee: Sol-Gel Technologies Ltd.Inventors: Ofer Toledano, Ofra Levy-Hacham, Ori Nov, Vered Ram
-
Publication number: 20230404917Abstract: This invention, in some embodiments thereof, relates to regimens, topical compositions comprising ruxolitinib, deuterated ruxolitinib or pharmaceutically acceptable salt thereof and uses thereof for the treatment of inflammatory skin conditions.Type: ApplicationFiled: November 17, 2021Publication date: December 21, 2023Applicant: Sol-Gel Technologies Ltd.Inventors: Moshe ARKIN, Ofer TOLEDANO, Karine NEIMANN
-
Publication number: 20230390291Abstract: Provided herein compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichthyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.Type: ApplicationFiled: August 22, 2023Publication date: December 7, 2023Applicant: Sol-Gel Technologies Ltd.Inventors: Moshe ARKIN, Marcel ZIGHELBOIM, Ori NOV, Ofer TOLEDANO, Karine NEIMANN
-
Publication number: 20230357113Abstract: The present invention relates to crystalline polymorphs of Tapinarof, e.g., Tapinarof crystalline Form B, Form C, and Form D, pharmaceutical compositions comprising the same, processes for preparation thereof, and uses thereof for treatment of skin disorders.Type: ApplicationFiled: May 8, 2023Publication date: November 9, 2023Applicant: Sol-Gel Technologies Ltd.Inventors: Moshe Arkin, Natalie Utsis, Ariel Mitelman, Bar Havazelt, Shai Dan
-
Publication number: 20230346716Abstract: Provided herein are topical composition comprising tapinarof and combination compositions comprising a therapeutically effective dose of tapinarof and a therapeutically effective dose of at least one additional active agent, selected from at least one corticosteroid, calcipotriene, at least one JAK inhibitor and combinations thereof, and a carrier suitable for topical administration. The above compositions are useful for the treatment, prevention or alleviation of skin disorders selected from psoriasis and atopic dermatitis and exhibit synergistic or additive effects which allow reducing the doses of the active agents in the compositions.Type: ApplicationFiled: July 11, 2023Publication date: November 2, 2023Applicant: Sol-Gel Technologies Ltd.Inventors: Moshe ARKIN, Danil Finkel-Moiseev, Hila Hakak Djerbi, Karine Neimann
-
Publication number: 20230338306Abstract: The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.Type: ApplicationFiled: March 30, 2023Publication date: October 26, 2023Applicant: Sol-Gel Technologies Ltd.Inventors: Ofer TOLEDANO, Karine NEIMANN, Danil FINKEL-MOISEEV, Maya ERLICH, Dorit MARCO
-
Publication number: 20230310395Abstract: The present disclosure, in some embodiments, relates to a low permeable topical composition comprising roflumilast, N-oxide of roflumilast or salts thereof, and to a method of treatment of a skin disorder by topical administration of said composition.Type: ApplicationFiled: August 24, 2021Publication date: October 5, 2023Applicant: Sol-Gel Technologies Ltd.Inventors: Moshe ARKIN, Ofer TOLEDANO, Karine NEIMANN, Hila HAKAK DJERBI
-
Patent number: 11633399Abstract: This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.Type: GrantFiled: January 8, 2020Date of Patent: April 25, 2023Assignee: Sol-Gel Technologies Ltd.Inventors: Moshe Arkin, Marcel Zighelboim, Ori Nov, Ofer Toledano, Karine Neimann
-
Patent number: 11628155Abstract: A regimen and a pharmaceutical composition for the treatment of rosacea are described. The regimen includes topically applying to the skin of a subject in need of such treatment a pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and the pharmaceutically acceptable carrier or excipient, where the benzoyl peroxide is the only active ingredient in the pharmaceutical composition, and the pharmaceutical composition is a cream or an emulsion.Type: GrantFiled: February 19, 2020Date of Patent: April 18, 2023Assignee: SOL-GEL TECHNOLOGIES LTD.Inventors: Ofer Toledano, Ori Nov
-
Publication number: 20230000786Abstract: Provided herein is a topical combination composition comprising tapinarof, a PDE4 inhibitor and optionally at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above compositions are useful for the treatment, prevention or alleviation of a skin disorder selected from psoriasis, dermatitis, acne, rosacea, ichthyosis, scaling skin, imbalance of skin barrier and tinea and exhibit synergistic and/or additive effects allowing to reduce the active agents amounts in the combination compositions.Type: ApplicationFiled: November 24, 2020Publication date: January 5, 2023Applicant: Sol-Gel Technologies Ltd.Inventors: Moshe ARKIN, Marcel ZIGHELBOIM, Karine NEIMANN
-
Patent number: 11541026Abstract: A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.Type: GrantFiled: December 3, 2021Date of Patent: January 3, 2023Assignee: SOL-GEL TECHNOLOGIES LTD.Inventors: Moshe Arkin, Karine Neimann, Ofer Toledano
-
Publication number: 20220387349Abstract: Provided herein is a topical composition comprising tapinarof and methods of treatment of cutaneous adverse effects caused by oncological therapy with the tapinarof composition. The tapinarof compositions of this invention are useful for the treatment, prevention or amelioration of cutaneous and/or mucosal adverse effect caused by oncological therapy selected from chemotherapy, immunotherapy, radiation therapy, targeted therapy, hormone therapy and stem cell transplant therapy.Type: ApplicationFiled: September 24, 2020Publication date: December 8, 2022Applicant: Sol-Gel Technologies LtdInventors: Moshe ARKIN, Marcel ZIGHELBOIM
-
Publication number: 20220331268Abstract: Provided herein is a topical combination composition comprising tapinarof, an additional AhR activator and optionally further comprising at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above compositions are useful for the treatment, prevention or alleviation of a skin disorder and exhibit synergistic and/or additive effects which allow reducing the amounts of the active agents in the compositions.Type: ApplicationFiled: September 24, 2020Publication date: October 20, 2022Applicant: Sol-Gel Technologies Ltd.Inventors: Moshe ARKIN, Marcel ZIGHELBOIM
-
Publication number: 20220287990Abstract: Provided herein is a topical combination composition and a method of treatment of an inflammatory skin condition by administration of said composition comprising at least one Janus kinase inhibitor (JAK inhibitor) and at least one additional active agent elected from benzoyl peroxide (BPO), at least one retinoid, tapinarof, at least one antibiotic, at least one antiandrogen, at least one acaricide and combinations thereof and a carrier suitable for topical administration. The JAK inhibitor and the at least one additional active agent exhibit an additive or synergistic effect, allowing to reduce the amounts of active agents in the composition.Type: ApplicationFiled: July 23, 2020Publication date: September 15, 2022Applicant: Sol-Gel Technologies Ltd.Inventors: Moshe ARKIN, Marcel ZIGHELBOIM, Ori NOV, Ofer TOLEDANO
-
Patent number: 11426378Abstract: A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in the pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75%.Type: GrantFiled: February 19, 2020Date of Patent: August 30, 2022Assignee: SOL-GEL TECHNOLOGIES LTD.Inventors: Ofer Toledano, Ofra Levy-Hacham, Ori Nov, Vered Ram
-
Publication number: 20220202737Abstract: The present invention, in some embodiments thereof, relates to treatment of hidradenitis suppurativa by topical or intralesional administration of a composition comprising tapinarof and optionally at least one additional active agent. The composition of the present invention is useful for the treatment, prevention or amelioration of hidradenitis suppurativa.Type: ApplicationFiled: March 26, 2020Publication date: June 30, 2022Applicant: Sol-Gel Technologies Ltd.Inventor: Moshe ARKIN
-
Publication number: 20220175732Abstract: Provided herein is a topical combination composition comprising a therapeutically effective amount of at least one acaricidal active agent, a therapeutically effective amount of at least one essentially non-acaricidal anti-inflammatory active agent and a carrier suitable for topical administration for the treatment of rosacea. Also provided are combination compositions optionally further comprising a vasoconstrictor.Type: ApplicationFiled: March 19, 2020Publication date: June 9, 2022Applicant: Sol-Gel Technologies Ltd.Inventor: Moshe ARKIN
-
Publication number: 20220175802Abstract: This invention is directed to a regimen administration of combination of minocycline and benzoyl peroxide and uses thereof for treating a skin disorder such as acne or rosacea.Type: ApplicationFiled: March 19, 2020Publication date: June 9, 2022Applicant: Sol-Gel Technologies Ltd.Inventors: Moshe ARKIN, Karine NEIMANN, Danil FINKEL-MOISEEV